Drugs / Anti-FLT3 CAR-T Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05445011 | Jun 2022 → Jun 2025 overdue | acute myeloid leukemia | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-FLT3 CAR-T Cell | “Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia” NCT05445011 ↗ |
| Known as | TAA05 Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05445011 ↗ |
| Modality | Cell therapy | “TAA05 Cell Injection is a kind of FLT3-targeted CAR-T cell” NCT05445011 ↗ |
| Target | FLT3 | “TAA05 Cell Injection is a kind of FLT3-targeted CAR-T cell” NCT05445011 ↗ |